Abstract
The unexpected discovery that somatic cells can be reprogrammed to a pluripotent state yielding induced pluripotent stem cells has made it possible to produce cardiovascular cells exhibiting inherited traits and disorders. Use of these cells in high throughput analyses should broaden our insight into fundamental disease mechanisms and provide many benefits for patients, including new therapeutics and individually tailored therapies. Here we review recent progress in generating induced pluripotent stem cell-based models of cardiovascular disease and their multiple applications in drug development.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Biomarkers / metabolism
-
Cardiovascular Agents / pharmacology*
-
Cardiovascular Diseases / chemically induced
-
Cardiovascular Diseases / drug therapy*
-
Cardiovascular Diseases / genetics
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / pathology
-
Drug Discovery / methods*
-
Gene Expression Regulation
-
Genetic Predisposition to Disease
-
Genomics
-
High-Throughput Screening Assays*
-
Humans
-
Induced Pluripotent Stem Cells / drug effects*
-
Induced Pluripotent Stem Cells / metabolism
-
Induced Pluripotent Stem Cells / pathology
-
Myocytes, Cardiac / drug effects*
-
Myocytes, Cardiac / metabolism
-
Myocytes, Cardiac / pathology
-
Phenotype
-
Risk Assessment
-
Toxicity Tests
Substances
-
Biomarkers
-
Cardiovascular Agents